Apollo Endosurgery Inc (NASDAQ:APEN) major shareholder Stonepine Capital, L.P. bought 22,845 shares of the stock in a transaction that occurred on Wednesday, January 3rd. The shares were bought at an average cost of $5.71 per share, with a total value of $130,444.95. Following the completion of the transaction, the insider now owns 2,560,314 shares in the company, valued at $14,619,392.94. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Major shareholders that own at least 10% of a company’s shares are required to disclose their sales and purchases with the SEC.

Stonepine Capital, L.P. also recently made the following trade(s):

  • On Saturday, December 29th, Stonepine Capital, L.P. bought 5,163 shares of Apollo Endosurgery stock. The shares were bought at an average cost of $5.56 per share, with a total value of $28,706.28.
  • On Tuesday, December 26th, Stonepine Capital, L.P. bought 5,287 shares of Apollo Endosurgery stock. The shares were bought at an average cost of $5.00 per share, with a total value of $26,435.00.
  • On Wednesday, December 20th, Stonepine Capital, L.P. acquired 45,434 shares of Apollo Endosurgery stock. The stock was acquired at an average cost of $4.50 per share, with a total value of $204,453.00.
  • On Friday, December 22nd, Stonepine Capital, L.P. acquired 185,157 shares of Apollo Endosurgery stock. The stock was acquired at an average cost of $4.85 per share, with a total value of $898,011.45.

Apollo Endosurgery Inc (APEN) traded down $0.07 during mid-day trading on Wednesday, hitting $5.82. The stock had a trading volume of 66,758 shares, compared to its average volume of 76,200. Apollo Endosurgery Inc has a 1 year low of $3.55 and a 1 year high of $19.95. The company has a debt-to-equity ratio of 0.58, a quick ratio of 2.00 and a current ratio of 2.54. The company has a market cap of $100.63, a price-to-earnings ratio of -0.27 and a beta of 0.44.

Hedge funds have recently bought and sold shares of the company. Stonepine Capital Management LLC bought a new position in shares of Apollo Endosurgery in the 3rd quarter worth about $11,067,000. King Luther Capital Management Corp bought a new position in shares of Apollo Endosurgery in the 3rd quarter worth about $2,567,000. Russell Investments Group Ltd. bought a new position in shares of Apollo Endosurgery in the 3rd quarter worth about $1,288,000. Woodmont Investment Counsel LLC bought a new position in shares of Apollo Endosurgery in the 3rd quarter worth about $220,000. Finally, JPMorgan Chase & Co. bought a new position in shares of Apollo Endosurgery in the 3rd quarter worth about $119,000. 23.67% of the stock is owned by hedge funds and other institutional investors.

APEN has been the subject of several research analyst reports. Northland Securities reissued a “buy” rating on shares of Apollo Endosurgery in a research report on Friday, October 27th. Zacks Investment Research raised Apollo Endosurgery from a “hold” rating to a “buy” rating and set a $4.75 price objective for the company in a research report on Thursday, November 2nd. Finally, ValuEngine raised Apollo Endosurgery from a “strong sell” rating to a “sell” rating in a research report on Wednesday. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating and three have given a buy rating to the stock. The stock presently has an average rating of “Hold” and an average target price of $9.44.

WARNING: This report was originally reported by American Banking News and is the property of of American Banking News. If you are reading this report on another publication, it was illegally stolen and republished in violation of U.S. & international copyright legislation. The original version of this report can be read at https://www.americanbankingnews.com/2018/01/03/stonepine-capital-l-p-purchases-22845-shares-of-apollo-endosurgery-inc-apen-stock.html.

About Apollo Endosurgery

Apollo Endosurgery, Inc, formerly Lpath, Inc, is a medical device company. The Company is focused on less invasive therapies for the treatment of obesity, as well as other gastrointestinal disorders. The Company’s device-based therapies are an alternative to invasive surgical procedures. The Company offers products in over 80 countries.

Insider Buying and Selling by Quarter for Apollo Endosurgery (NASDAQ:APEN)

Receive News & Ratings for Apollo Endosurgery Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Apollo Endosurgery and related companies with MarketBeat.com's FREE daily email newsletter.